Does Anagrelide accelerate fibrosis?

Current research has no clear conclusion on whether anagrelide (Anagrelide) accelerates fibrosis. Fibrosis refers to the excessive proliferation of fibrous tissue in a certain tissue or organ. It can be a pathological reaction or a part of normal tissue repair.

Anagrelide, a drug used to treat idiopathic thrombocythemia (ET), mainly controls platelet count by inhibiting platelet production and release. In ET patients, platelet counts remain elevated, which may lead to complications such as thrombosis and bleeding. The mechanism of action of anagrelide is mainly to target the maturation and differentiation process of megakaryocytes to reduce the production of platelets.

Research on whether anagrelide is directly related to fibrosis is limited. Some studies suggest that anagrelide may be associated with fibrosis in certain pathological conditions. For example, anagrelide may be associated with the progression of liver fibrosis in some experimental studies in animal models. However, these findings are unclear and further research is needed to confirm this association.

In addition, long-term observations of patients with essential thrombocythemia taking anagrelide in clinical studies and clinical practice have not shown clear evidence that anagrelide accelerates fibrosis. However, taking into account individual patient differences and disease characteristics, patients taking anagrelide still require regular monitoring and clinical evaluation.

Anagrelide is not yet on the market in China, so patients cannot purchase it domestically and need to purchase the drug through overseas channels. Anagrelide only has the original drug. Outside the mainland, there is the Hong Kong version of the original drug and the foreign Turkish original drug. The price is around 1280 yuan.

xa0